AngioDynamics’ NanoKnife for Prostate Tissue Ablation Assessed in PRESERVE Study

July 23, 2025—AngioDynamics, Inc. announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the company’s NanoKnife system to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa).

The PRESERVE study was led by Coprincipal Investigators Jonathan Coleman, MD, and Arvin George, MD. The findings were published by Dr. George et al in European Urology. The study met its primary effectiveness endpoint, demonstrating the performance of the NanoKnife system for the ablation of prostate tissue in patients with intermediate-risk PCa, noted AngioDynamics.

The company stated that the minimally invasive, nonthermal, radiation-free NanoKnife ablation technology is designed to treat prostate tissue by using IRE technology. In late 2024, NanoKnife received FDA clearance for prostate tissue ablation after completion of the PRESERVE study.

AngioDynamics advised that the PRESERVE study, which enrolled 121 patients at 17 clinical sites, was conducted in collaboration with the Society of Urologic Oncology Clinical Trials Consortium. Patients in the study met the key inclusion criteria: age > 50 years with organ-confined, grade group 2 or 3 PCa; clinical stage ≤T2c; prostate-specific antigen (PSA) ≤ 15 ng/mL; or PSA density < 0.15 ng/mL².

As summarized in the company’s press release, 84% of men were free from in-field, clinically significant disease (defined by the Delphi consensus criterion) at 12 months postprocedure. The study also demonstrated strong quality-of-life outcomes: urinary continence was largely preserved (97% at baseline vs 96% at 12 months) and 84% of patients with good sexual function at baseline maintained erections sufficient for penetration at 12 months, noted the company.

“The PRESERVE data supports the long-term data that we are seeing in practice; patients are benefiting from effective, targeted treatment without compromising their quality of life,” commented Dr. Coleman in the AngioDynamics press release. “The ability to preserve urinary and sexual function while treating prostate tissue with precision is a meaningful advancement for both clinicians and patients.”